Covance

Covance announces executive appointments

Friday, May 4, 2012 04:08 AM

Covance, a Princeton, N.J.-based provider of drug development services, has promoted Bill Klitgaard to corporate senior vice president and chief information officer, and Alison Cornell to corporate vice president and chief financial officer, effective May 8 upon approval by the board of directors.

More... »

Covance-BML lab to expand in Japan

Thursday, April 26, 2012 03:07 PM

CRO Covance of Princeton, N.J., and BML, a Japanese laboratory testing company, will expand the Covance-BML Clinical Trial Laboratory (CB Trial Lab) in Kawagoe City, Saitama Prefecture, to enhance the capacity and capabilities in the region. The companies, which opened the lab together in 2010 as part of a five-year agreement, will launch several new expansion-related services this month.

More... »

ACT Oncology names Julia Amo as COO

Wednesday, March 28, 2012 12:02 PM

ACT Oncology, a niche oncology service provider, has appointed Julia Amo, MBA, PMP, as chief operating officer.

More... »

Covance to be exclusive drug development provider for BioPontis

Friday, February 3, 2012 01:25 PM

Covance has signed a three-year, exclusive integrated drug development agreement with BioPontis Alliance to manage early development of scientific discoveries from academia. Covance will become BioPontis Alliance’s sole provider of drug development services, including discovery support, pre-clinical, bioanalytical, CMC, clinical, central labs and commercialization.

More... »

Covance enters R&D collaboration

Thursday, January 19, 2012 08:30 AM

Covance, Inserm Transfert, a subsidiary of Inserm, and seed investment company Inserm Transfert Initiative have signed a four-year R&D collaboration.

More... »

Cetero Research expands senior management team

Tuesday, December 27, 2011 11:49 AM

Cetero Research has reported two new appointments to its senior management team. Michael C. Fillios was named chief administrative officer, with leadership responsibility and oversight of human resources, information technology, project management, marketing and client services. David Coggin was named vice president, biometrics. He will oversee the operational management of PK/PD, data management, miostatistics and medical writing services.

More... »

Survey: Sponsor’s choice of central lab affects investigator’s satisfaction with trial experience

Monday, December 12, 2011 09:04 AM

The choice of a central lab can greatly affect a principal investigator’s satisfaction level while conducting a clinical trial. 

More... »

Hoffman joins Theorem Clinical Research

Tuesday, November 8, 2011 03:35 PM

Theorem Clinical Research, previously Omnicare Clinical Research, has named Marc Hoffman, MD, senior vice president and general manager for their newly formed pharmaceutical development business unit. In his new role, Hoffman will have strategic oversight for Theorem’s core CRO operation, including project management, clinical monitoring, SMART (site management and patient recruitmenT), and pharmaceutics. He will also oversee the company’s medical operations. 

More... »

Survey: Covance central laboratory services ranks first

Wednesday, November 2, 2011 11:13 AM

Covance central laboratory services ranked first, by a wide margin, in an independent global survey of 550 physician investigators participating in clinical trials. The majority (54%) of the study participants named Covance central laboratory services as their "most preferred" central laboratory, with investigators citing Covance three times more often than the nearest competitor. Investigators also reported having the "best overall relationship" with Covance, rating it 8.4 on a scale of 1 to 10.

More... »

Survey: 80% of big pharma companies restructuring to strategically outsource more trials to CROs

Monday, October 31, 2011 08:00 AM

According to a recent survey from William Blair, about 80% of big pharma companies either are in the process of restructuring or have already completed restructuring plans to strategically outsource more of their trials to CROs.

More... »